VOR
Vor Biopharma Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 46 | +15 | 17.25M | $317.51M | +16 | −1 |
| Q1 2026 | 31 | +7 | 8.52M | $152.06M | +8 | −1 |
| Q4 2025 | 24 | -1 | 5.67M | $74.16M | — | −1 |
| Q3 2025 | 11 | +1 | 478.12K | $23.29M | +2 | −1 |
| Q2 2025 | 7 | -2 | 5.57M | $9.03M | — | −2 |
| Q1 2025 | 6 | -1 | 1.58M | $1.14M | — | −1 |
| Q4 2024 | 7 | 0 | 1.73M | $1.92M | — | — |
| Q3 2024 | 6 | 0 | 1.74M | $1.22M | +1 | −1 |
| Q2 2024 | 6 | — | 1.49M | $1.49M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 495.30K | — | $495,300 | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 424.83K | — | $424,933 | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 424.83K | — | $424,933 | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 389.64K | — | $389,638 | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 84.64K | — | $84,645 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Marshall Wace ✦ | 81.11K | — | $81,114 | 0.0% | n/c | 1 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 11.20K | — | $11,204 | 0.0% | n/c | 1 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 11.20K | — | $11,204 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 79 holders, 40.44M shares, $716.36M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.